ArticleJournal, genetic engineering & biotechnology2025
Comprehensive examination of demographic, psychological, cognitive, biochemical, and genetic profiles of methamphetamine addicts.
Article in Journal, genetic engineering & biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Methamphetamine (MA) addiction is a serious public health concern with wide-ranging neurobiological and behavioral effects. This study aimed to assess the demographic, psychological, cognitive, biochemical, and genetic profiles of individuals with methamphetamine dependence, focusing on neurotransmitter levels and the expression of addiction- and aggression-related genes. Sixty male methamphetamine users and thirty age-matched healthy controls were recruited. Participants underwent psychological assessments, cognitive testing, and biochemical evaluation of serotonin and dopamine levels using ELISA. Gene expression of SLC6A4 and COMT was quantified via real-time PCR. Significant alterations were observed in the methamphetamine group compared to controls, including reduced serotonin (17.1 ± 3.1 vs. 20.5 ± 3.2 ng/mL; p = 0.002) and dopamine levels (46.3 ± 7.2 vs. 52.4 ± 6.5 ng/mL; p = 0.015), as well as down-regulation of SLC6A4 (0.64-fold vs. 1.00; p = 0.001) and up-regulation of COMT (1.47-fold vs. 1.00; p = 0.028). These biochemical and genetic changes were correlated with increased aggression and cognitive impairments. The findings underscore the impact of prolonged MA use on neurochemical balance and gene expression, contributing to the development of aggressive behaviors and addictive patterns. Tailored treatment strategies that integrate genetic and psychological profiling, along with longitudinal monitoring, are essential to address the multifactorial nature of methamphetamine addiction and improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.